Intralesional Methotrexate for the Treatment of Keratoacanthoma: Retrospective Study and Review of the Korean Literature
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Although intralesional methotrexate (MTX) isan effective, nonsurgical treatment of keratoacanthoma (KA),there have not been many reports of on the MTX treatmentfor KA in Korea. Objective: The purpose of this study was toevaluate the clinical efficacy of the intralesional MTX for thetreatment of KA in Korean patients. Methods: We retrospectivelystudied seven patients with KA who receivedintralesional injection of MTX in our department. Theefficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated withintralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Koreanpatients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treatedwith an intralesional MTX, including seven from ourinstitution and four from the Korean literature. Ten of the 11patients (91%) showed a complete resolution with anintralesional MTX. No adverse events were observed duringthe treatment and the follow-up periods. No recurrence wasfound during the follow-up. In therapeutic analysis, theKorean patients required 2 to 7 injections (mean 4.6 injections)to achieve a tumor resolution with the mean time to clearingat 7.6 weeks. Conclusion: Intralesional MTX can be aneffective and safe non-operative treatment modality for mostKoreans with KA.
Abstract
Background: Although intralesional methotrexate (MTX) isan effective, nonsurgical treatment of keratoacanthoma (KA),there have not been many reports of on the MTX treatmentfor KA in Korea. Objective: The purpose of this study was toevaluate the clinical efficacy of the intralesional MTX for thetreatment of KA in Korean patients. Methods: We retrospectivelystudied seven patients with KA who receivedintralesional injection of MTX in our department. Theefficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated withintralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Koreanpatients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treatedwith an intralesional MTX, including seven from ourinstitution and four from the Korean literature. Ten of the 11patients (91%) showed a complete resolution with anintralesional MTX. No adverse events were observed duringthe treatment and the follow-up periods. No recurrence wasfound during the follow-up. In therapeutic analysis, theKorean patients required 2 to 7 injections (mean 4.6 injections)to achieve a tumor resolution with the mean time to clearingat 7.6 weeks. Conclusion: Intralesional MTX can be aneffective and safe non-operative treatment modality for mostKoreans with KA.
참고문헌 (16)
- Beham A, "Keratoacanthoma:a clinically distinct variant of well differentiated squamous cell carcinoma", Adv Anat Pathol, 5, pp.269~280 (1998)
- Schwartz RA, "Keratoacanthoma: a clinico-pathologic enigma", Dermatol Surg, 30, pp.326~333 (2004)
- Kim CY, "Treatment of keratoacanthomas with intralesional 5-fluorouracil and methotrexate", Korean J Dermatol, 39, pp.1175~1178 (2001)
- 유동오, "Methotrexate 병변내 주사로 치료한 각화극세포종 2예", 대한피부과학회지, 41(5), pp.555~558 (2003), 대한피부과학회
- Hong HS, "A case of giant keratoacanthoma of the lower lip treated with intralesional methotrexate", Korean J Otolaryngol-Head Neck Surg, 40, pp.1858~1862 (1997)
- 신재빈, "Methotrexate 병변내 주사로 치료한 거대 각화극세포종 2예", 대한피부과학회지, 44(7), pp.902~904 (2006), 대한피부과학회
- Melton JL, "Treatment of keratoacanthomas with intralesional methotrexate", J Am Acad Dermatol, 25, pp.1017~1023 (1991)
- Stranc MF, "Conservative treatment of keratoacanthoma", Ann Plast Surg, 2, pp.525~530 (1979)
- Schwartz RA, "The keratoacanthoma: a review", J Surg Oncol, 12, pp.305~317 (1979)
- Annest NM, "Intralesional methotrexate treatment for keratoacanthoma tumors:a retrospective study and review of the literature", J Am Acad Dermatol, 56, pp.989~993 (2007)
- Olsen EA, "The pharmacology of methotrexate", J Am Acad Dermatol, 25, pp.306~318 (1991)
- Parker CM, "Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil", J Am Acad Dermatol, 14, pp.770~777 (1986)
- Kirby JS, "Intralesional chemotherapy for nonmelanoma skin cancer: a practical review", J Am Acad Dermatol, 63, pp.689~702 (2010)
- Good LM, "Intralesional agents in the management of cutaneous malignancy: a review", J Am Acad Dermatol, 64, pp.413~422 (2011)
- Cohen PR, "Pancytopenia after a single intradermal infiltration of methotrexate", J Drugs Dermatol, 4, pp.648~651 (2005)
- Goebeler M, "Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration", Arch Dermatol, 137, pp.1104~1105 (2001)